Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINERVA trial of abemaciclib plus endocrine therapy with digital side effect management in HR-positive/HER2-negative advanced or metastatic breast cancer
2024-511209-49-00Phase 4Authorised
- Sponsor
- University Hospital Ulm
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label trial of abemaciclib in breast cancer (4 arms), sponsored by University Hospital Ulm. Primary endpoint: Progression-free survival. Planned start Apr 2022; status: authorised.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-511209-49-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511209-49-00.